VEGF 165b (C-Term) Antikörper
Kurzübersicht für VEGF 165b (C-Term) Antikörper (ABIN360957)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- C-Term
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human.
-
Aufreinigung
- Affinity Chromatography on Protein G
-
Sterilität
- 0.2 μm filtered
-
Immunogen
- Recombinant Human VEGF-165b C-terminal peptide
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
-
Western Blot: 1/100 - 1/1000. Immunohistochemistry on frozen section: 1/20 - 1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Rekonstitution
- Restore with 0.5 mL sterile PBS to the concentration of 0.2 mg/mL
-
Konzentration
- 0.2 mg/mL
-
Buffer
- Lyophilized from a 0.2 μm filtered solution in Phosphate-Buffered Saline (PBS)
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Prior to reconstitution store at 2-8 °C. Following reconstitution store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- VEGF 165b
-
Hintergrund
- VEGF165b is an mRNA splice variant of VEGF. Alternative exon usage results in a 165 aa product that is identical to VEGF165 except for 6 unique amino acids at the C-terminus. VEGF165b inhibits proliferation and migration of endothelial cells and is down-regulated in renal cell carcinomas.Synonyms: VEGF, VEGF-A, VEGFA, VPF, Vascular endothelial growth factor A, Vascular permeability factor
Target
-